https://www.onhealthcare.tech/p/fda-closes-the-503b-bulks-door-on-7b8Thoughts on Healthcare Markets & Technologyen2026-05-04T16:33:01+00:00Part II: FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide: How the April 30 Proposal Kills the Compounded GLP-1 Supply Chain and Draws a Hard Line Between Clinical Need and Economic Needhttps://www.onhealthcare.tech/p/fda-closes-the-503b-bulks-door-on-a34Thoughts on Healthcare Markets & Technologyen2026-05-04T16:30:26+00:00Part I: FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide: How the April 30 Proposal Kills the Compounded GLP-1 Supply Chain and Draws a Hard Line Between Clinical Need and Economic Needhttps://www.onhealthcare.tech/p/the-preclinical-signal-in-routine-e7cThoughts on Healthcare Markets & Technologyen2026-05-04T16:28:12+00:00Part II: The Preclinical Signal in Routine Abdominal CT: How Mayo's REDMOD and the Pre-Diagnostic Pancreas Force a Rethink of Cancer Screening Math, Workflow Economics, and the Multimodal Future of Risk Inferencehttps://www.onhealthcare.tech/p/the-preclinical-signal-in-routine-8e5Thoughts on Healthcare Markets & Technologyen2026-05-04T16:25:55+00:00Part I: The Preclinical Signal in Routine Abdominal CT: How Mayo's REDMOD and the Pre-Diagnostic Pancreas Force a Rethink of Cancer Screening Math, Workflow Economics, and the Multimodal Future of Risk Inferencehttps://www.onhealthcare.tech/p/the-fda-real-time-clinical-trial-251Thoughts on Healthcare Markets & Technologyen2026-05-04T16:22:45+00:00The FDA Real Time Clinical Trial Announcement Quietly Dissolves Phase Gates, Breaks Biotech Capital Markets Plumbing, and Opens a Founder Sized Hole in Trial Infrastructure, Financing, and Workflowhttps://www.onhealthcare.tech/p/profluents-225b-lilly-deal-and-why-c11Thoughts on Healthcare Markets & Technologyen2026-05-04T16:20:33+00:00Profluent's $2.25B Lilly Deal and Why Treating Proteins as a Language Modeling Problem Is a Bigger Story Than the Headline Suggests: Scaling Laws, Synthetic Biology, and the Compute Substrate Thesishttps://www.onhealthcare.tech/p/how-ai-value-based-care-bundles-medicare-1a8Thoughts on Healthcare Markets & Technologyen2026-05-04T16:18:16+00:00How AI, Value Based Care Bundles, Medicare Payment Compression, and IMG-Driven Residency Match Dynamics Will Reshuffle the Wealthiest Physician Specialty Rankings Over the Next Five to Ten Yearshttps://www.onhealthcare.tech/p/the-fda-just-rewrote-the-rules-for-c4aThoughts on Healthcare Markets & Technologyen2026-05-04T16:15:00+00:00The FDA Just Rewrote the Rules for Gene Therapy Approval & Most Investors Haven't Noticed Yet: The Plausible Mechanism Framework and NGS Safety Guidance That Could Reshape Rare Disease Investmenthttps://www.onhealthcare.tech/p/cms-0062-p-deep-dive-what-the-2026-e34Thoughts on Healthcare Markets & Technologyen2026-05-04T16:12:03+00:00CMS-0062-P Deep Dive: What the 2026 Interoperability and Prior Authorization for Drugs Proposed Rule Actually Means for Health Tech Investors and Entrepreneurshttps://www.onhealthcare.tech/p/the-category-2-peptide-unwind-how-cacThoughts on Healthcare Markets & Technologyen2026-05-04T16:10:05+00:00The Category 2 Peptide Unwind: How a Rogan Appearance, 14 Withdrawn Nominations & a July PCAC Docket Will Reprice the Compounding Pharmacy Stack, GLP-1 Gray Market, and Longevity Clinic Supply Chainhttps://www.onhealthcare.tech/p/amazon-bio-discovery-what-aws-just-13cThoughts on Healthcare Markets & Technologyen2026-05-04T16:07:06+00:00Amazon Bio Discovery: What AWS Just Launched, Why It Actually Matters for Drug Development, and What Health Tech Investors Need to Understand About the Platform War Now Playing Out in Life Scienceshttps://www.onhealthcare.tech/p/goodfire-ai-and-the-billion-dollar-00fThoughts on Healthcare Markets & Technologyen2026-05-04T16:04:36+00:00Goodfire AI and the Billion Dollar Bet on Neural Network Interpretability: Why Reverse Engineering Foundation Models Matters for Health Tech Investors Watching the Life Sciences AI Stack Take Shapehttps://www.onhealthcare.tech/p/gpt-rosalind-lands-what-openais-first-42cThoughts on Healthcare Markets & Technologyen2026-05-04T16:01:11+00:00GPT-Rosalind Lands: What OpenAI's First Domain-Specific Life Sciences Model, the Codex Life Sciences Plugin & the Trusted Access Program Actually Meanhttps://www.onhealthcare.tech/p/the-cms-national-provider-directory-0e3Thoughts on Healthcare Markets & Technologyen2026-05-04T15:59:11+00:00The CMS national provider directory: a complete analysis of 27.2 million healthcare records in the entrepreneurial opportunity that they representhttps://www.onhealthcare.tech/p/bundles-are-back-now-mandatory-and-21fThoughts on Healthcare Markets & Technologyen2026-05-04T15:56:29+00:00Bundles Are Back, Now Mandatory and Nationwide: A Builder's Field Guide to the New Companies, Tools, and Channels That Should Get Built Around CMS's CJR-X Lower-Extremity Joint Replacement Modelhttps://www.onhealthcare.tech/p/how-late-2025-and-early-2026-earnings-5e0Thoughts on Healthcare Markets & Technologyen2026-05-04T15:54:21+00:00How Late 2025 and Early 2026 Earnings Calls Expose the Medicare Advantage Pullback, the Migration of Margin From Insurance to Services, and the Quiet Redistribution of Healthcare Profit Poolshttps://www.onhealthcare.tech/p/the-ai-drug-discovery-capital-stack-eedThoughts on Healthcare Markets & Technologyen2026-05-04T15:51:31+00:00The AI Drug Discovery Capital Stack in 2026: Who Has Raised the Most, Why Their Technical Approaches Actually Differ, and Which Recent Industry and Academic Papers Are Worth a Real Readhttps://www.onhealthcare.tech/p/how-commercial-insurers-self-insured-133Thoughts on Healthcare Markets & Technologyen2026-05-04T15:48:52+00:00How Commercial Insurers, Self-Insured Employers, PBMs, and Manufacturers Are Turning GLP-1 Pharmacy Benefits Into Active Managed-Access Operating Systems and Where the Infrastructure Opportunity Sitshttps://www.onhealthcare.tech/p/the-prior-auth-api-economy-how-cms-887Thoughts on Healthcare Markets & Technologyen2026-05-04T15:47:05+00:00The Prior Auth API Economy: How CMS-0057-F, CMS-0062-P, Da Vinci FHIR Rails, State Gold Carding Laws, AI Guardrails, and the AHIP/BCBSA 257M Commitment Turn UM Into a Programmable Transactionhttps://www.onhealthcare.tech/p/start-here-how-to-get-the-most-out-e80Thoughts on Healthcare Markets & Technologyen2026-05-04T15:44:01+00:00Start Here: How to Get the Most Out of This Newsletterhttps://www.onhealthcare.tech/p/programmable-medical-necessity-and-ae1Thoughts on Healthcare Markets & Technologyen2026-05-04T15:42:04+00:00Programmable Medical Necessity & the Pricing Computation Layer: How Prior Auth API Infrastructure, Claims-Derived Transparency Data, and ERISA Fiduciary Litigation Are Rewiring Commercial Healthcarehttps://www.onhealthcare.tech/p/the-balance-model-pause-the-glp-1-84bThoughts on Healthcare Markets & Technologyen2026-05-04T15:39:56+00:00The BALANCE Model Pause, the GLP-1 Bridge Extension Thru Dec 2027 & What the 80% Part D Participation Threshold Miss Signals About Medicare's First Real Attempt to Negotiate Anti-Obesity Drug Coveragehttps://www.onhealthcare.tech/p/the-cms-fda-rapid-coverage-pathway-c82Thoughts on Healthcare Markets & Technologyen2026-05-04T15:35:21+00:00The CMS-FDA RAPID Coverage Pathway Is a Capital Markets Event Disguised as a Coverage Policy: What the Regulatory-Reimbursement Clock Synch Means for Medtech Investment & Device Commercializationhttps://www.onhealthcare.tech/p/what-does-17-pharma-mfn-deals-are-875Thoughts on Healthcare Markets & Technologyen2026-05-04T15:31:05+00:00What does 17 pharma MFN deals are underneath the press releases: the real primary source stack, the GLP1 numbers, TrumpRX plumbing, and where the new adjudication layer gets monetizedhttps://www.onhealthcare.tech/p/commercial-value-based-care-has-quietly-7f9Thoughts on Healthcare Markets & Technologyen2026-05-04T15:18:51+00:00Commercial Value-Based Care Has Quietly Turned Into a Real Messy, Multi-Payer Operating Layer Wedged Btwn Employer Cost Pressure, Payer Network Strategy, Specialty Economics & Provider Margin Realityhttps://www.onhealthcare.tech/p/goodfire-ai-and-the-billion-dollar-53bThoughts on Healthcare Markets & Technologyen2026-05-04T14:13:58+00:00Goodfire AI and the Billion Dollar Bet on Neural Network Interpretability: Why Reverse Engineering Foundation Models Matters for Health Tech Investors Watching the Life Sciences AI Stack Take Shapehttps://www.onhealthcare.tech/p/what-judy-faulkners-freakonomicsThoughts on Healthcare Markets & Technologyen2026-05-04T11:58:04+00:00What Judy Faulkner’s Freakonomics interview tells us about Epic’s Ten Commandments, the Purpose Trust succession, the 30 percent R&D rate, and the live antitrust fight in healthcarehttps://www.onhealthcare.tech/p/fda-closes-the-503b-bulks-door-onThoughts on Healthcare Markets & Technologyen2026-05-03T13:24:25+00:00FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide — Part II